Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).

Aleesha Shaik,Mikhail Kosiborod,James A de Lemos,Qi Gao,Katherine E Mues,Shushama Alam,Deepak L Bhatt,Christopher P Cannon,Christie M Ballantyne,Robert S Rosenson

Clinical cardiology（2022）

引用 0|浏览3

暂无评分

摘要

Despite the recommendations of multiscociety guidelines, statin use, while high, is not ubiquitous and rates of high-intensity statin and ezetimibe use remain low in patients with CKD. There remains a significant opportunity to optimize LLT and achieve atheroprotective cholesterol levels in the CKD population.

查看译文

关键词

atherosclerosis,cholesterol,chronic kidney disease,coronary artery disease,ezetimibe,lipids,statins

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要